Patent Application for Cancer Treatment Combination Therapies

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published October 23rd, 2024

Detected March 27th, 2026

Summary

The USPTO has published a new patent application (US20260083816A1) detailing methods for treating cancer using combination therapies. The application, filed by inventors Erlinda M. Gordon and Fredrick L. Hall, focuses on inhibiting cyclin proteins and targeting pathways that promote cyclin activity.

View original document View source feed page

What changed

This document is a publication of a patent application, not a regulatory rule or guidance. It describes a novel method for treating cancer by combining therapies that inhibit cyclin proteins with agents targeting other molecules involved in cyclin activity. The application details potential therapeutic agents that target surface biomarkers or intracellular proteins.

While this is a patent application and not a binding regulation, it signals potential future developments in cancer treatment. Companies involved in oncology drug development should be aware of this intellectual property filing. There are no immediate compliance obligations or deadlines associated with a patent application publication, but it may influence future research and development strategies.

Source document (simplified)

← USPTO Patent Applications

METHODS OF TREATING CANCER BY TARGETING DRIVERS

Application US20260083816A1 Kind: A1 Mar 26, 2026

Inventors

Erlinda M. Gordon, Fredrick L. Hall

Abstract

The present disclosure provides methods of using combination therapies to treat cancer. These methods are based on inhibiting cyclin proteins along with proteins along the Cyclin Axis. Thus, a method of the disclosure may generally be practiced by administering to an individual having cancer a cytocidal inhibitor of cyclin, along with a therapeutic agent that targets other molecules involved in pathways that promote cyclin activity. These therapeutic agents may target biomarkers on the surface of a cancer cell and that promote cyclin activity as well as intracellular proteins involved in pathways that affect, or are affected by, cyclin activity.